Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).

Affiliation auteurs!!!! Error affiliation !!!!
TitreActivity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).
Type de publicationJournal Article
Year of Publication2015
AuteursPouessel D, Terrisse SAarab, Mouillet G, Breitkopf K, Theodore C, Lobbedez FJoly, Roubaud G, Flechon A, Tourani J-M, Massard C, Thiery-Vuillemin A, Oudard S, Sevin E, Chevret S, Culine S
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.15_suppl.e16094